The research may lead to treatment for infected individuals and also increase the understanding of genetic diseases such as amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and spinal muscular atrophy (SMA), the leading genetic cause of infantIn addition, "I plan to discuss strategic alternatives for Repligen in light of the positive Phase 1 results of 3039 for the potential treatment of Spinal Muscular Atrophy (SMA), and the decision of the FDA to require additional clinical
Read more ...
Hiç yorum yok:
Yorum Gönder